Frontiers in Oncology最新文献

{"title":"Retraction: Upregulation of CCT-3 induces breast cancer cell proliferation through miR-223 competition and Wnt/β-catenin signaling pathway activation.","authors":"","doi":"10.3389/fonc.2025.1575634","DOIUrl":"https://doi.org/10.3389/fonc.2025.1575634","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fonc.2020.533176.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1575634"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving equity and wellness in cancer care with people of Latin American and African Descent: a study protocol.","authors":"Anna Santos Salas, Sharon M Watanabe, Aynharan Sinnarajah, Nahyeni Bassah, Fleur Huang, Jacqueline Alcalde-Castro, Harkeert Judge, Hannah M O'Rourke, Pilar Camargo Plazas, Bukola Salami, María J Santana, Omar Abdel Rahman, Iqmat Iyiola, Tracy Wildeman, Lisa Vaughn, Sadia Ahmed","doi":"10.3389/fonc.2025.1469037","DOIUrl":"10.3389/fonc.2025.1469037","url":null,"abstract":"<p><strong>Background: </strong>Cancer inequities such as late access to cancer screening and diagnosis affect people of African and Latin American descent in Canada. These inequities in addition to experiences of racism and discrimination and unequal living and working conditions are detrimental to their wellness. We aim to delineate together with people of African and Latin American descent a patient-oriented pathway to improve their equity and wellness in cancer care.</p><p><strong>Methods: </strong>This is a 3-year community-based and patient-oriented participatory research study. The study will take place in Alberta and Ontario and will involve 125 participants including people with cancer, family and community members of African and Latin American descent, and health care providers. We will conduct in-depth interviews with patients and families and focus groups with community members. Together with patient partners and community collaborators, we will delineate a patient-oriented pathway in cancer care to improve equity and wellness for people of African and Latin American descent in Canada. Finally, we will explore the acceptability of the pathway with a small sample of patients, families and health care providers.</p><p><strong>Conclusion: </strong>This study will advance our knowledge of equity and wellness in people with advanced cancer from racialized communities in Canada; and increase our understanding of how racialized populations live through a cancer diagnosis. The study will also generate knowledge of how a patient-oriented health equity pathway can contribute to reduce cancer inequities in the care of our study populations.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1469037"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF^V600-mutant melanoma in Spain: the BECARE (GEM-2002) trial.","authors":"Ainara Soria, Pedro Sanchez Mauriño, Juan José Serrano Domingo, Regina García Galindo, Silvia Sequero, Lourdes Gutiérrez Sanz, Guillermo Crespo, Roberto Díaz-Beveridge, Teresa Puértolas, Pedro López, Joaquín Fra Rodríguez, Rafael López Castro, Cristina Aguayo, Javier Valdivia, Alberto Jacobo Cunquero-Tomás, Gretel Benítez, Pablo Ayala de Miguel, Enrique Espinosa, Eva Muñoz-Couselo, Begoña Campos, Lourdes García Sánchez, Pablo Cerezuela-Fuentes","doi":"10.3389/fonc.2025.1466185","DOIUrl":"10.3389/fonc.2025.1466185","url":null,"abstract":"<p><strong>Purpose: </strong>Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B) has demonstrated efficacy and tolerability in phase III clinical trials, and is the standard of care for advanced/metastatic BRAF^V600-mutant melanoma. However, real-life evidence is limited, particularly in patients pre-treated with immune checkpoint inhibitors (ICI).</p><p><strong>Patients and methods: </strong>BECARE GEM 2002 was a retrospective, non-interventional study aimed at investigating the real-world effectiveness and tolerability of EB in patients with unresectable or metastatic BRAF^V600-mutant melanoma conducted at 21 sites in Spain. The primary objective of this study was to characterise the population of patients receiving EB and assess the efficacy and tolerability of EB in real life. The study included patients treated according to standard clinical practice with EB as the 1^st line or 2^nd line after progression to ICI for an unresectable or metastatic stage. Patients who previously received treatment with BRAF and/or MEK inhibitor, other than as adjuvants, that ended ≥ 6 m before EB were not eligible.</p><p><strong>Results: </strong>From September 2021 to March 2023, 117 patients were included; 89 (76.1%) and 28 (23.9%) patients received EB as 1^st line and 2^nd line, respectively. The median follow-up was 13.8 months (95% CI: 12.0-17.4). In patients with EB as 1^st line treatment, ORR and median PFS were 75% and 12 months (95% CI: 9.4-18.6), respectively. In patients with EB as 2^nd line treatment after ICI, ORR and median PFS were 77.8% and 12.5 months (95% CI: 6.6-NA), respectively. In patients with brain metastasis ORR and median PFS were 70.8% and 6.3 months (95% CI: 6.1-10.3). Treatment-related adverse events of grade ≥3 were reported in 17 (14.5%) patients; transaminitis (9.4%) and diarrhoea (2.6%) were the most frequent adverse events.</p><p><strong>Conclusion: </strong>In this real-world study, EB treatment demonstrated effectiveness and a consistent safety profile in patients with BRAF^V600-mutant melanoma treated according to standard clinical practice, including in those with prior ICI treatment and of brain metastasis; therefore, EB is a feasible treatment option for unresectable and metastatic melanoma.Clinical trial identification: REec: 0004-2021-OBS.</p><p><strong>Clinical trial identification: </strong>REec: 0004-2021-OBS.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1466185"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacroplasty with or without screw fixation for sacral metastatic tumors.","authors":"Evan P Cox, Sean Tutton, Matthew Scheidt, Brandon M Key, John C Neilson, Adam N Wooldridge, Meena Bedi, Donald A Hackbarth, David M King","doi":"10.3389/fonc.2025.1494377","DOIUrl":"10.3389/fonc.2025.1494377","url":null,"abstract":"<p><strong>Introduction: </strong>Cementation (sacroplasty) with or without ablation has been shown to improve pain and function for patients with sacral metastatic disease. Percutaneous screw fixation with sacroplasty (PSFS) may provide superior outcomes in select patients.</p><p><strong>Methods: </strong>Thirty patients with sacral metastases who underwent sacroplasty with or without ablation and screw fixation at a single institution were retrospectively reviewed. Patients were compared based on treatment (PSFS or sacroplasty alone) and fracture status (pathological or impending) with an ANCOVA. Traumatic fractures were excluded. Patients were followed for 4.4 months on average (range, 2 weeks to 36.5 months). Functional outcomes were assessed using the Musculoskeletal Tumor Society (MSTS) score. The rate of secondary procedures as well as changes in narcotic usage were noted.</p><p><strong>Results: </strong>Patients with pathological fractures who underwent PSFS demonstrated increased postoperative MSTS scores compared to those who underwent sacroplasty (51% ± 19 versus 25% ± 13, p = 0.005). Patients with impending pathological fractures who underwent PSFS did not demonstrate statistically significant increased postoperative MSTS scores compared to those who underwent sacroplasty alone (38% ± 17 versus 32% ± 12, p = 0.72).</p><p><strong>Discussion: </strong>PSFS may provide additional benefit for patients with pathological fractures, while sacroplasty alone may be sufficient for those with impending pathologic fractures secondary to sacral metastatic disease. This study was limited by its retrospective design and sample size; however, the results may aid in treatment indications for sacral metastases and guide further research <i>Level of Evidence</i> Level III, Therapeutic Study.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1494377"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SATB2 promotes radiation resistance of esophageal squamous cell carcinoma by regulating epithelial-to-mesenchymal transition via the Wnt/β-catenin pathway.","authors":"Chen Lin, Youyi Wu, Yuchen Qian, Jiayi Li, Youdi He, Huang Yu, Congying Xie, Huafang Su","doi":"10.3389/fonc.2025.1543426","DOIUrl":"10.3389/fonc.2025.1543426","url":null,"abstract":"<p><strong>Purpose: </strong>Radioresistance remains a predominant factor contributing to local recurrence in esophageal squamous cell carcinoma (ESCC). SATB2, as a transcriptional co-gene, may affect the radioresistance of cancer cells. Consequently, this study aims to elucidate the mechanism by which SATB2 modulates radiotherapy resistance in esophageal cancer.</p><p><strong>Methods: </strong>We identified highly expressed genes associated with radioresistance in ESCC using the MSigDB database and conducted survival correlation analysis. A radioresistant esophageal squamous cell carcinoma cell line (KYSE150R) was established using the gradient dose method, and RT-qPCR was used to detect the expression of SATB2 in KYSE150 and KYSE150R cells. CCK-8, Transwell, colony formation assay, and cell scratching were performed to determine and evaluate cell proliferation, cell migration, and cell invasion. Furthermore, the expression levels of mRNA and protein were correlated using WB and RT-qPCR. Mitochondrial membrane potential and apoptosis detection kits were used to evaluate the level of apoptosis. Finally, a mouse subcutaneous xenograft tumor model was employed to elucidate the role of SATB2 on the radiotherapy resistance of ESCC <i>in vivo</i>.</p><p><strong>Results: </strong>Bioinformatics analysis indicated that SATB2 is linked to increased drug resistance in esophageal cancer. The results demonstrated that suppression of SATB2 decelerates cell proliferation and migration, accelerates apoptosis, inhibits the GSK-3β (Ser9) phosphorylation, and reduces β-catenin and target gene C-myc. The addition of the Wnt/β-catenin signaling pathway agonist (CHIR-99021) reversed these effects. Xenograft studies in mice revealed that knockdown of SATB2 reduced ESCC radioresistance.</p><p><strong>Conclusion: </strong>We concluded that SATB2 may dysregulate the Wnt/β-catenin pathway, thereby facilitating EMT progression and conferring radioresistance.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1543426"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical factors influencing residual subcutaneous tissue after skin-sparing and nipple-sparing mastectomy with immediate breast reconstruction.","authors":"Menekse Turna, Hale Basak Caglar","doi":"10.3389/fonc.2025.1516479","DOIUrl":"10.3389/fonc.2025.1516479","url":null,"abstract":"<p><strong>Background: </strong>Skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) have emerged as increasingly preferred alternatives to traditional mastectomy, largely due to their enhanced cosmetic outcomes and elevated levels of patient satisfaction. Nonetheless, the oncological safety and implications associated with residual breast tissue in these surgical procedures continue to raise significant concerns. The objective of this study is to evaluate the influence of various clinical and surgical factors on residual subcutaneous tissue in patients undergoing SSM and NSM.</p><p><strong>Methods: </strong>This retrospective cohort study encompassed breast cancer patients who underwent postoperative radiotherapy following SSM and NSM with immediate breast reconstruction from November 2020 to April 2024. Clinical and demographic data, including age, tumor size, axillary staging, molecular subtype, genetic analysis, and surgical details, were systematically collected. Additionally, radiation treatment planning CT scans were assessed to measure residual subcutaneous tissue thickness at multiple anatomical regions. The correlation between residual subcutaneous tissue thickness and clinical factors was subsequently analyzed.</p><p><strong>Results: </strong>The median age was 45 years (range, 31-61). Among the total patients, 20 underwent SSM (52.63%), and 18 underwent NSM (47.37%). An acceptable residual subcutaneous tissue distance (≤5 mm) was observed in 21 breasts (55.26%), while 17 breasts (44.74%) did not meet this criterion. Analysis demonstrated a statistically significant but modest positive correlation between RFT thickness and age (r = 0.38, p = 0.02), minimal positive correlation was observed between RFT thickness and clinical tumor size (r = 0.08, p = 0.042). A significant effect of contralateral breast surgery on residual subcutaneous tissue thickness was noted (F = 8.38, p < 0.001). Additionally, the results also revealed a statistically significant inverse correlation between RFT thickness and axillary involvement (r = -0.18, p = 0.005), suggesting that thicker flaps are associated with reduced axillary involvement. There was no significant difference in RFT thickness between NSM and SSM groups (Chi² = 0.47, p = 0.491).</p><p><strong>Conclusion: </strong>A significant proportion of patients undergoing SSM and NSM exhibit residual subcutaneous tissue thickness that exceeds acceptable limits, which may vary based on clinical and pathological factors. Further research involving larger cohorts and prospective designs is essential to identify additional contributing factors and optimize indications for postoperative radiotherapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1516479"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility study of 4D-online monitoring of density gradients induced by lung cancer treatment using carbon ions.","authors":"Claire-Anne Reidel, Enrico Pierobon, Felix Horst, Lévana Gesson, Athena Paz, Christian Graeff, Timo Steinsberger, Klemens Zink, Matthias Witt, Yannick Senger, Christian Finck, Marie Vanstalle, Chiara La Tessa, Marco Durante, Uli Weber, Christoph Schuy","doi":"10.3389/fonc.2025.1502960","DOIUrl":"10.3389/fonc.2025.1502960","url":null,"abstract":"<p><p>Tumor motion is a major challenge for scanned ion-beam therapy. In the case of lung tumors, strong under- and overdosage can be induced due to the high density gradients between the tumor- and bone tissues compared to lung tissues. This work proposes a non-invasive concept for 4D monitoring of high density gradients in carbon ion beam therapy, by detecting charged fragments. The method implements CMOS particle trackers that are used to reconstruct the fragment vertices, which define the emission points of nuclear interactions between the primary carbon ions and the patient tissues. A 3D treatment plan was optimized to deliver 2 Gy to a static spherical target volume. The goodness of the method was assessed by comparing reconstructed vertices measured in two static cases to the ones in a non-compensated moving case with an amplitude of 20 mm. The measurements, performed at the Marburg Ion-Beam Therapy Center (MIT), showed promising results to assess the conformity of the delivered dose. In particular to measure overshoots induced by high density gradients due to motion with 83.0 ± 1.5% and 92.0 ± 1.5% reliability based on the ground truth provided by the time-resolved motor position and depending on the considered volume and the iso-energy layers.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1502960"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: MDS: new scientific and clinical developments.","authors":"Sabine Blum, Argiris Symeonidis, Ulrich Germing","doi":"10.3389/fonc.2025.1568681","DOIUrl":"10.3389/fonc.2025.1568681","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1568681"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging, clinical, and histopathological challenges in diagnosing retroperitoneal extraskeletal osteosarcoma.","authors":"Jiro Ichikawa, Tomonori Kawasaki, Kojiro Onohara, Masanori Wako, Naofumi Taniguchi, Satoshi Ochiai, Hirotaka Haro","doi":"10.3389/fonc.2025.1454055","DOIUrl":"10.3389/fonc.2025.1454055","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1454055"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of initial platelet count and post-induction platelet recovery in elderly AML patients: associated with circulating cytokines.","authors":"Chun Ling, Neng-Neng Cao, Xiao-Wei Niu, Shi-Yun Xu, Wen-Yu Gong, Wen-Qiang Bao, Qi-Chuan Jin, Yin Wang, Jing Wu, Chang-Zhi Zhao, Wen-Jing Fu, Qi-Guo Zhang, Shan-Shan Feng, Dao-Yuan Li","doi":"10.3389/fonc.2025.1534158","DOIUrl":"10.3389/fonc.2025.1534158","url":null,"abstract":"<p><strong>Objective: </strong>Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with various clinical features influencing its prognosis. The aim of this study to evaluate the impact of platelet count at diagnosis and platelet recovery after induction chemotherapy on the survival outcomes of elderly AML patients.</p><p><strong>Methods: </strong>A total of 109 elderly patients with AML who were treated in our center between 2017 and 2023 were evaluated. According to the median platelet counts at the time of new diagnosis, the cases were divided into a low platelet counts group (≤40×10⁹/L, n=54) and a high platelet count group (>40×10⁹/L, n=55). Platelet recovery times were accepted as the periods from the beginning of induction chemotherapy to a platelet count of ≥20×10⁹/L 3 days in a row, respectively. The median time to platelet recovery was 25 days (range12-47) for all patients. Therefore, platelet recovery in the first 25 days was defined as early platelet recovery and at >25 days it was defined as late platelet recovery.</p><p><strong>Results: </strong>Low platelet counts at diagnosis and early recovery of platelet counts after induction therapy indicate longer overall survival (OS) and Leukemia-free survival (LFS). Patients with high platelet counts at diagnosis and those with delayed platelet recovery after induction therapy exhibited elevated levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Additionally, patients with high platelet counts at diagnosis also had relatively higher levels of interleukin-8 (IL-8).</p><p><strong>Conclusion: </strong>Platelets can be used as a prognostic biomarker for elderly AML and may be associated with circulating cytokines.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1534158"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}